SONN (Sonnet BioTherapeutics Holdings) ROCE %: 0.00% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SONN Sonnet BioTherapeutics Holdings Inc SONN
28 GF Score
Price $1.26
View Full Analysis

What is Sonnet BioTherapeutics Holdings ROCE %?

Sonnet BioTherapeutics Holdings SONN 28 ROCE % is 0.00% as of Jun. 2025. GuruFocus rates SONN with a GF Score™ of 28/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sonnet BioTherapeutics Holdings's annualized ROCE % for the quarter that ended in Jun. 2025 was 0.00%.

Sonnet BioTherapeutics Holdings  (NAS:SONN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sonnet BioTherapeutics Holdings ROCE % Related Terms

Sonnet BioTherapeutics Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Sonnet BioTherapeutics Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sonnet BioTherapeutics Holdings ROCE % Chart

Sonnet BioTherapeutics Holdings Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
ROCE %
Get a 7-Day Free Trial -8,193.41 -196.29 -297.34 0.00 0.00

Sonnet BioTherapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -484.17 -1,129.18 -629.44 -716.48 0.00
SONN
28GF Score
Sonnet BioTherapeutics Holdings Inc SONN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sonnet BioTherapeutics Holdings ROCE % Calculation

Sonnet BioTherapeutics Holdings's annualized ROCE % for the fiscal year that ended in Sep. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2024 )  (A: Sep. 2023 )(A: Sep. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2024 )  (A: Sep. 2023 )(A: Sep. 2024 )
=-11.849/( ( (5.429 - 5.525) + (2.771 - 3.21) )/ 2 )
=-11.849/( (-0.096+-0.439)/ 2 )
=-11.849/-0.2675
=4,429.53 %

Sonnet BioTherapeutics Holdings's ROCE % of for the quarter that ended in Jun. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2025 )  (Q: Mar. 2025 )(Q: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2025 )  (Q: Mar. 2025 )(Q: Jun. 2025 )
=-15.224/( ( (3.836 - 3.174) + (2.055 - 5.102) )/ 2 )
=-15.224/( ( 0.662 + -3.047 )/ 2 )
=-15.224/-1.1925
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Sonnet BioTherapeutics Holdings (SONN) has a ROCE % of 0.00% as of Jun. 2025.
Is Sonnet BioTherapeutics Holdings' ROCE % too high?
Sonnet BioTherapeutics Holdings' current ROCE % is 0.00%. Overall, Sonnet BioTherapeutics Holdings has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Sonnet BioTherapeutics Holdings' ROCE % compare to CING and BOLD?
Sonnet BioTherapeutics Holdings' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Sonnet BioTherapeutics Holdings's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonnet BioTherapeutics Holdings stock overvalued right now?
Sonnet BioTherapeutics Holdings (SONN) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Sonnet BioTherapeutics Holdings' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sonnet BioTherapeutics Holdings (SONN), the current ROCE % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sonnet BioTherapeutics Holdings Business Description

Address 100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
28GF Score

Get the complete analysis for SONN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price